Cyclophosphamide

• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended
  2024-511594-30-00 Phase III 4 countries Kite Pharma Inc.
• RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter c… Ended
  2024-517881-40-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom… Ended
  2022-501380-40-00 Phase II 3 countries Merck Sharp & Dohme LLC
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Ended
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III 17 countries Amgen Inc.
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended
  2023-507286-25-00 Phase II 2 countries LYSARC
• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended
  2023-505210-18-00 Phase III 4 countries AstraZeneca AB
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len… Ended
  2023-505850-16-00 Phase III 16 countries Janssen - Cilag International
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended
  2022-500237-92-00 Phase III 11 countries Incyte Corp.
• CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended
  2024-519174-39-00 Phase I (FiH) 1 country Ospedale Pediatrico Bambino Gesu
• Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended
  2024-513659-34-00 Phase I/II 1 country LYSARC
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended
  2023-509358-72-00 Phase III 9 countries Acerta Pharma B.V.
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended
  2023-504828-25-00 Phase I/II 9 countries Genmab A/S
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• POLAR BEAR Ended
  2022-502887-19-00 Phase III 6 countries Region Skane
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended
  2023-506588-32-00 Phase III 10 countries Janssen - Cilag International
• Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extr… Ended
  2024-514963-24-00 Phase II 2 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended
  2023-506587-13-00 Phase II 5 countries Janssen - Cilag International
• A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early… Ended
  2022-501102-35-00 Phase III 2 countries Region Skåne
• Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9… Ended
  2024-511849-19-00 Phase II 2 countries Institut Jules Bordet
• Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended
  2024-511641-18-00 Phase II 1 country Fondazione Italiana Linfomi Ets

Showing 121–144 of 185 trials